Aldeyra Therapeutics Inc. (NASDAQ:ALDX) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.01.

Aldeyra Therapeutics (NASDAQ:ALDX) opened at 6.50 on Wednesday. The company has a 50 day moving average of $6.61 and a 200-day moving average of $6.05. The company’s market cap is $40.59 million. Aldeyra Therapeutics has a one year low of $3.39 and a one year high of $8.19.

Earnings History for Aldeyra Therapeutics (NASDAQ:ALDX)

A number of equities research analysts have issued reports on the company. Cowen and Company reiterated a “buy” rating on shares of Aldeyra Therapeutics in a research note on Tuesday. HC Wainwright assumed coverage on shares of Aldeyra Therapeutics in a report on Monday, September 26th. They set a “buy” rating and a $18.00 price objective for the company. Finally, Zacks Investment Research raised shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a report on Tuesday, October 25th. Five equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $14.30.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Northern Trust Corp increased its position in Aldeyra Therapeutics by 3.9% in the third quarter. Northern Trust Corp now owns 12,846 shares of the biotechnology company’s stock worth $100,000 after buying an additional 480 shares in the last quarter. Vanguard Group Inc. increased its position in Aldeyra Therapeutics by 3.1% in the second quarter. Vanguard Group Inc. now owns 125,125 shares of the biotechnology company’s stock worth $712,000 after buying an additional 3,718 shares in the last quarter. BlackRock Fund Advisors increased its position in Aldeyra Therapeutics by 1,944.6% in the second quarter. BlackRock Fund Advisors now owns 20,630 shares of the biotechnology company’s stock worth $117,000 after buying an additional 19,621 shares in the last quarter. Knoll Capital Management LP acquired a new position in Aldeyra Therapeutics during the third quarter worth about $1,038,000. Finally, Baker BROS. Advisors LP acquired a new position in Aldeyra Therapeutics during the third quarter worth about $1,110,000. Institutional investors own 51.01% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

5 Day Chart for NASDAQ:ALDX

Receive News & Stock Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related stocks with our FREE daily email newsletter.